Otilimab

Phase 2Monoclonal antibody

GSK

Otilimab is one of 64 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

LupusActive, not recruiting

COVID-19Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

LupusPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

Otilimab

GSK

Phase 2

1 3

Glucocorticoid

AbbVie

Preclinical

1 4

Nadroparin

GSK

Preclinical

1 5

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 6

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 7

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 8

Exoflo

DDirect Biologics, LLC

Preclinical

3 9

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

1 10

Tpa

UUniversity of Florida

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Terminated· GSK logo

GSK·Phase 3·NCT04333147·2,916 enrolled

Tics1 trial

A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

Withdrawn· GSK logo

GSK·Phase 1·NCT05304130

COVID-191 trial

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

Completed· GSK logo

GSK·Phase 2·NCT04376684·1,156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Otilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Otilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Otilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: GSK

Otilimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Tics1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News